Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Dapagliflozin 10 mg vs Forxiga 10 mg in healthy Thai participants under fasting
TCTR20260310006Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Primary endpoint: Bioequivalence based on pharmacokinetic parameters. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20260310006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260310006.